Page last updated: 2024-09-03

imatinib mesylate and Leukemia, Myelomonocytic, Chronic

imatinib mesylate has been researched along with Leukemia, Myelomonocytic, Chronic in 23 studies

Research

Studies (23)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	14 (60.87)	29.6817
2010's	9 (39.13)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Garcia-Manero, G; Khoury, JD; Loghavi, S; Shah, S	1
Falchi, L; Verstovsek, S	1
Finke, CM; Lasho, TL; Pardanani, A; Patnaik, MM; Tefferi, A	1
Deininger, MW; Eiring, AM; Gligorich, K; Hein, T; Kelley, TW; Khorashad, JS; Marth, GT; Mason, CC; O'Hare, T; Pomicter, AD; Qiao, Y; Reid, AG; Tantravahi, SK; Yan, D	1
Apostolidis, J; Baltadakis, I; Evangelou, K; Gorgoulis, VG; Harhalakis, N; Karakasis, D; Papadakis, V; Sfikakis, PP	1
Ames, HM; Crawford, BD; Downing, JR; Gauvin, AM; Li, L; Lucas, PC; Morrison, SJ; Oravecz-Wilson, KI; Philips, ST; Ross, TS; Sitwala, K; Yilmaz, OH	1
Bardi, A; Cavazzini, F; Ciccone, M; Cuneo, A; Gorello, P; La Starza, R; Mecucci, C; Rigolin, GM	1
Gotlib, J; Pardanani, A; Tefferi, A	1
Mattar, M	1
Agati, L; Basciani, S; Fabbri, A; Gnessi, L; Lubrano, C; Mariani, S; Spera, G; Ulisse, S	1
Chahchad, S; Gogtay, J; Jadhav, S; Purandare, S	1
Di Raimondo, F; Stagno, F; Vigneri, P	1
Barrett, J; Dunbar, CE; Magnusson, MK; Meade, KE; Nakamura, R	1
Biondi, A; Cazzaniga, G; Gambacorti-Passerini, C; Gunby, RH; Le Coutre, P; Pogliani, E; Specchia, G; Tassi, E	1
Alo, G; Arrigo, C; Barresi, G; Pitini, V; Righi, M; Teti, D	1
Albitar, M; Cortes, J; Faderl, S; Garcia-Manero, G; Giles, F; Kantarjian, H; Letvak, L; O'Brien, S; Rios, MB; Salvado, A; Talpaz, M; Thomas, D	1
Houshmand, P; Zlotnik, A	1
Shannon, KM; Van Etten, RA	1
Drechsler, M; Germing, U; Hildebrandt, B; Kündgen, A; Royer-Pokora, B	1
Cools, J; Lierman, E	1
Cho, SG; Kim, DB; Kim, M; Lee, HJ; Shin, J; Yeom, JO	1
Elliott, MA; Mesa, RA; Tefferi, A	1
Hochhaus, A	1

Reviews

5 review(s) available for imatinib mesylate and Leukemia, Myelomonocytic, Chronic

Article	Year
Eosinophilia in Hematologic Disorders. Immunology and allergy clinics of North America, 2015, Volume: 35, Issue:3 Topics: Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Leukemia; Leukemia, Myelomonocytic, Chronic; Receptor, Fibroblast Growth Factor, Type 1; Receptor, Platelet-Derived Growth Factor alpha; Receptor, Platelet-Derived Growth Factor beta	2015
Hypereosinophilic syndrome and clonal eosinophilia: point-of-care diagnostic algorithm and treatment update. Mayo Clinic proceedings, 2010, Volume: 85, Issue:2 Topics: Alemtuzumab; Algorithms; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Agents; Benzamides; Causality; Decision Trees; Diagnosis, Differential; Eosinophilia; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myelomonocytic, Chronic; Mastocytosis; mRNA Cleavage and Polyadenylation Factors; Mutation; Myelodysplastic Syndromes; Piperazines; Pyrimidines; Receptor, Fibroblast Growth Factor, Type 1; Receptors, Platelet-Derived Growth Factor	2010
Targeting tumor cells. Current opinion in cell biology, 2003, Volume: 15, Issue:5 Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Antineoplastic Agents; Benzamides; Chemokines; Drug Therapy; Gene Expression Profiling; Genes, abl; Genes, erbB-2; Humans; Imatinib Mesylate; Integrins; Leukemia, Myelomonocytic, Chronic; Lymphoma, Non-Hodgkin; Metalloproteases; Neoplasm Metastasis; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptors, Platelet-Derived Growth Factor; Rituximab; Stomach Neoplasms; Trastuzumab	2003
Focus on myeloproliferative diseases and myelodysplastic syndromes. Cancer cell, 2004, Volume: 6, Issue:6 Topics: Anemia, Refractory; Antineoplastic Agents; Benzamides; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemia, Myelomonocytic, Chronic; Models, Biological; Myelodysplastic Syndromes; Myeloproliferative Disorders; Piperazines; Pyrimidines; Signal Transduction	2004
[Selective tyrosine kinase inhibitor imatinib (STI571) in haematological and oncological disease]. Deutsche medizinische Wochenschrift (1946), 2002, Mar-01, Volume: 127, Issue:9 Topics: Adult; Antineoplastic Agents; Benzamides; Carcinoma, Small Cell; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Cytogenetics; Drug Resistance, Neoplasm; Drug Therapy, Combination; Enzyme Inhibitors; Female; Fusion Proteins, bcr-abl; Gastrointestinal Neoplasms; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myelomonocytic, Chronic; Lung Neoplasms; Male; Mastocytosis; Multicenter Studies as Topic; Mutation; Neoplasms; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Primary Myelofibrosis; Protein-Tyrosine Kinases; Pyrimidines; Remission Induction; Time Factors	2002

Other Studies

18 other study(ies) available for imatinib mesylate and Leukemia, Myelomonocytic, Chronic

Article	Year
Discovery of imatinib-responsive FIP1L1-PDGFRA mutation during refractory acute myeloid leukemia transformation of chronic myelomonocytic leukemia. Journal of hematology & oncology, 2014, Mar-27, Volume: 7 Topics: Benzamides; Eosinophilia; Humans; Imatinib Mesylate; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Chronic; Male; Middle Aged; mRNA Cleavage and Polyadenylation Factors; Mutation; Oncogene Proteins, Fusion; Piperazines; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Treatment Outcome	2014
Targeted next generation sequencing of PDGFRB rearranged myeloid neoplasms with monocytosis. American journal of hematology, 2016, Volume: 91, Issue:3 Topics: Aged; Aged, 80 and over; Databases, Factual; Disease-Free Survival; Electronic Health Records; Gene Rearrangement; Humans; Imatinib Mesylate; Leukemia, Myelomonocytic, Chronic; Leukocyte Count; Male; Middle Aged; Monocytes; Myeloproliferative Disorders; Receptor, Platelet-Derived Growth Factor beta; Treatment Outcome	2016
Rapid conversion of chronic myeloid leukemia to chronic myelomonocytic leukemia in a patient on imatinib therapy. Leukemia, 2016, Volume: 30, Issue:11 Topics: Aged; Antineoplastic Agents; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myelomonocytic, Chronic; Male; Mutation	2016
Is imatinib mesylate a promising drug in scleroderma due to extensive chronic graft-versus-host disease? Leukemia & lymphoma, 2009, Volume: 50, Issue:3 Topics: Benzamides; Chronic Disease; Female; Graft vs Host Disease; Humans; Imatinib Mesylate; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myelomonocytic, Chronic; Male; Middle Aged; Peripheral Blood Stem Cell Transplantation; Piperazines; Pyrimidines; Scleroderma, Systemic; Treatment Outcome	2009
Persistence of leukemia-initiating cells in a conditional knockin model of an imatinib-responsive myeloproliferative disorder. Cancer cell, 2009, Aug-04, Volume: 16, Issue:2 Topics: Animals; Antineoplastic Agents; Benzamides; Core Binding Factor Alpha 2 Subunit; Disease Models, Animal; DNA-Binding Proteins; Drug Resistance, Neoplasm; Gene Knock-In Techniques; Genotype; Hematopoietic Stem Cells; Humans; Imatinib Mesylate; Leukemia, Myelomonocytic, Chronic; Mice; Mice, Transgenic; Myeloproliferative Disorders; Oncogene Proteins, Fusion; Piperazines; Pyrimidines; RUNX1 Translocation Partner 1 Protein; Spleen	2009
Trisomy 8 in PDGFRB-negative cells in a patient with imatinib-sensitive chronic myelomonocytic leukemia and t(5;16)(q33;p13), PDGFRB-NDE1 fusion. Cancer genetics and cytogenetics, 2009, Volume: 194, Issue:1 Topics: Antineoplastic Agents; Benzamides; Chromosomes, Human, Pair 16; Chromosomes, Human, Pair 5; Chromosomes, Human, Pair 8; Humans; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Karyotyping; Leukemia, Myelomonocytic, Chronic; Microtubule-Associated Proteins; Oncogene Proteins, Fusion; Piperazines; Pyrimidines; Receptor, Platelet-Derived Growth Factor beta; Reverse Transcriptase Polymerase Chain Reaction; Translocation, Genetic; Trisomy	2009
Failure of copy Imatib (CIPLA, India) to maintain hematologic and cytogenetic responses in chronic myeloid leukemia in chronic phase. International journal of hematology, 2010, Volume: 91, Issue:1 Topics: Antineoplastic Agents; Benzamides; Drug Design; Drugs, Generic; Female; Humans; Imatinib Mesylate; Leukemia, Myelomonocytic, Chronic; Middle Aged; Piperazines; Pyrimidines; Treatment Failure	2010
Severe oligozoospermia in a young man with chronic myeloid leukemia on long-term treatment with imatinib started before puberty. Fertility and sterility, 2011, Mar-01, Volume: 95, Issue:3 Topics: Adolescent; Antineoplastic Agents; Benzamides; Humans; Imatinib Mesylate; Leukemia, Myelomonocytic, Chronic; Male; Oligospermia; Piperazines; Puberty; Pyrimidines; Severity of Illness Index	2011
Response to the case report by Mattar: Generic Imatinib (Imatib, Cipla) in a patient with chronic myeloid leukemia in chronic phase. International journal of hematology, 2010, Volume: 92, Issue:5 Topics: Antineoplastic Agents; Benzamides; Drugs, Generic; Humans; Imatinib Mesylate; Leukemia, Myelomonocytic, Chronic; Piperazines; Pyrimidines; Treatment Failure	2010
Imatinib discontinuation: realistic for patients with chronic myeloid leukaemia achieving complete molecular remission? The Lancet. Oncology, 2011, Volume: 12, Issue:2 Topics: Antineoplastic Agents; Benzamides; Humans; Imatinib Mesylate; Leukemia, Myelomonocytic, Chronic; Piperazines; Pyrimidines; Remission Induction	2011
Activity of STI571 in chronic myelomonocytic leukemia with a platelet-derived growth factor beta receptor fusion oncogene. Blood, 2002, Aug-01, Volume: 100, Issue:3 Topics: Adult; Antineoplastic Agents; Benzamides; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemia, Myelomonocytic, Chronic; Male; Oncogene Proteins, Fusion; Piperazines; Pyrimidines; Receptor, Platelet-Derived Growth Factor beta; Remission Induction; Treatment Outcome	2002
Sensitivity to imatinib but low frequency of the TEL/PDGFRbeta fusion protein in chronic myelomonocytic leukemia. Haematologica, 2003, Volume: 88, Issue:4 Topics: Animals; Benzamides; Cell Line, Transformed; Cell Transformation, Neoplastic; Humans; Imatinib Mesylate; Leukemia, Myelomonocytic, Chronic; Mice; Oncogene Proteins, Fusion; Piperazines; Pyrimidines; Reverse Transcriptase Polymerase Chain Reaction	2003
Response to STI571 in chronic myelomonocytic leukemia with platelet derived growth factor beta receptor involvement: a new case report. Haematologica, 2003, Volume: 88, Issue:5 Topics: Aged; Antineoplastic Agents; Benzamides; Enzyme Inhibitors; Eosinophilia; Humans; Imatinib Mesylate; Leukemia, Myelomonocytic, Chronic; Male; Myelodysplastic Syndromes; Myeloproliferative Disorders; Piperazines; Pyrimidines; Receptor, Platelet-Derived Growth Factor beta; Translocation, Genetic	2003
Results of imatinib mesylate therapy in patients with refractory or recurrent acute myeloid leukemia, high-risk myelodysplastic syndrome, and myeloproliferative disorders. Cancer, 2003, Jun-01, Volume: 97, Issue:11 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Chronic; Middle Aged; Myelodysplastic Syndromes; Myeloproliferative Disorders; Piperazines; Polycythemia Vera; Primary Myelofibrosis; Pyrimidines; Recurrence	2003
Fusion of H4/D10S170 to PDGFRbeta in a patient with chronic myelomonocytic leukemia and long-term responsiveness to imatinib. Annals of hematology, 2007, Volume: 86, Issue:5 Topics: Benzamides; Cytoskeletal Proteins; Gene Fusion; Humans; Imatinib Mesylate; Leukemia, Myelomonocytic, Chronic; Mutant Chimeric Proteins; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Receptor, Platelet-Derived Growth Factor beta; Translocation, Genetic	2007
TV6 and PDGFRB: a license to fuse. Haematologica, 2007, Volume: 92, Issue:2 Topics: Benzamides; Chromosome Aberrations; ETS Translocation Variant 6 Protein; Humans; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Leukemia, Myelomonocytic, Chronic; Myeloproliferative Disorders; Piperazines; Proto-Oncogene Proteins c-ets; Pyrimidines; Receptor, Platelet-Derived Growth Factor beta; Remission Induction; Repressor Proteins; Translocation, Genetic	2007
Sustained response to low-dose imatinib mesylate in a patient with chronic myelomonocytic leukemia with t(5;12)(q33;p13). Acta haematologica, 2008, Volume: 119, Issue:1 Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Child; Child, Preschool; Chromosomes, Human, Pair 12; Chromosomes, Human, Pair 5; Dose-Response Relationship, Drug; Female; Humans; Imatinib Mesylate; Leukemia, Myelomonocytic, Chronic; Male; Middle Aged; Piperazines; Pyrimidines; Translocation, Genetic; Treatment Outcome	2008
Adverse events after imatinib mesylate therapy. The New England journal of medicine, 2002, Feb-28, Volume: 346, Issue:9 Topics: Aged; Antineoplastic Agents; Benzamides; Female; Humans; Imatinib Mesylate; Leukemia, Myelomonocytic, Chronic; Middle Aged; Piperazines; Primary Myelofibrosis; Pyrimidines; Radiography; Splenic Rupture; Splenomegaly	2002